A global survey shows robot anxiety drops when people encounter robots in real life
Updated
March 13, 2026 2:25 PM

Ameca the humanoid robot, featuring a grey rubber face. PHOTO: ADOBE STOCK
People often assume robots make people uneasy everywhere. But a new global study suggests something more nuanced. Robot anxiety tends to be highest in places where people rarely see robots in real life. Where robots are more visible, attitudes are often far more positive. That insight comes from a global study by Hexagon AB, which surveyed 18,000 participants across nine major markets. The research explored how adults and children think about robots and how those views change depending on everyday exposure.
In the United Kingdom, anxiety about robots is the highest among the countries studied. Around 52% of adults say they feel worried that something might go wrong when they think about interacting with or working alongside robots. South Korea sits at the other end of the spectrum, with only 29% reporting similar concerns. One factor appears to explain much of the gap: familiarity.
British adults are among the least likely to have encountered robots in real life. Only about 30% say they have seen or used one. In contrast, countries where robots are more visible tend to report greater comfort. China offers the clearest example. Around 75% of adults there say they have seen or interacted with robots. At the same time, 81% say they feel excited about the technology’s future potential.
The study suggests that attitudes toward robots are not fixed. Instead, they shift depending on where people encounter them and what tasks they perform. When robots are seen solving clear, practical problems, confidence tends to rise.
Across the surveyed countries, adults report the highest comfort levels with robots working in factories and warehouses. Around 63% say they are comfortable with robots in those environments. These are settings where tasks are clearly defined and safety standards are well understood. Acceptance drops in more personal spaces. Only 46% say they feel comfortable with robots in the home, while comfort falls further to 39% when robots are imagined in classrooms.
In other words, context matters. People appear more willing to accept robots when they take on physically demanding or dangerous work. Half of the respondents say improved safety is one of the main advantages of robotics in those environments. A similar share point to productivity gains as another benefit. Another finding challenges a common assumption about public fears. Job loss is often described as the biggest concern surrounding robotics. But the study suggests security risk worries people more.
Around 51% of adults say their biggest concern about robots at work is the possibility that the machines could be hacked or misused. That fear outweighs worries about physical malfunction or injury, which stand at 41%. Concerns about being replaced at work appear at the same level.
For many respondents, the issue is not simply whether robots can perform tasks. It is whether the systems controlling them are secure. According to researchers involved in the study, these concerns reflect how people evaluate emerging technologies. Instead of having a single opinion about robotics, people tend to judge each situation individually.
A robot helping assemble products in a factory may feel acceptable. The same technology operating in more sensitive environments can raise different questions. Dr. Jim Everett, an associate professor in moral psychology, says trust in artificial intelligence and robotics is often misunderstood. People are not simply asking whether they trust the technology, he notes. They are thinking about specific tools performing specific roles.
A robot assisting in a classroom or helping in healthcare carries different expectations than an AI system used in defense or surveillance. Even though these technologies are often grouped together in public debates, people evaluate them differently depending on their purpose.
Finally, the study also highlights another important factor shaping public attitudes: experience. When people actually encounter robots, fear often declines. Michael Szollosy, a robotics researcher involved in the project, says reactions tend to change quickly when individuals meet a robot for the first time.
The idea of an autonomous machine can feel intimidating in theory. But when people see a small service robot or an industrial machine performing a straightforward task, the reaction is often much calmer. Exposure can shift perceptions from abstract fears to practical understanding.
That shift matters because robotics is moving steadily into everyday environments. From manufacturing and logistics to healthcare and public services, machines capable of autonomous or semi-autonomous work are becoming more common.
As that happens, the study suggests public confidence may depend less on technical breakthroughs and more on visibility and transparency. Burkhard Boeckem, chief technology officer at Hexagon AB, argues that trust grows when people understand what robots are designed to do and where their limits lie.
Anxiety tends to increase when systems feel invisible or poorly understood. Clear boundaries and clear explanations can have the opposite effect. When people see robots working safely alongside humans, performing well-defined tasks and operating within clear rules, the technology becomes easier to accept.
In that sense, the future of robotics may depend as much on public familiarity as on engineering. The machines themselves are advancing quickly. But the relationship between humans and robots is still being negotiated. For now, the study offers a simple insight: the more people encounter robots in everyday life, the less mysterious they become. And once the mystery fades, the conversation often changes from fear to curiosity.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM

Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.